May 02, 2022 7:45am EDT Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
Feb 24, 2022 4:05pm EST OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results
Feb 17, 2022 8:00am EST OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022
Feb 15, 2022 11:30am EST Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
Jan 21, 2022 8:00am EST Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
Jan 20, 2022 8:00am EST JAPAN’S MHLW APPROVES PFIZER AND OPKO’S NGENLA® (SOMATROGON), A NEW LONG-ACTING TREATMENT FOR PEDIATRIC GROWTH HORMONE DEFICIENCY
Jan 18, 2022 11:51am EST Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Jan 05, 2022 4:05pm EST OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Dec 23, 2021 8:00am EST OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients